Market research: Accu-Chek Insight insulin pump users, all ages, across UK. £60 incentive

Market research opportunity:
Accu-Chek Insight insulin pump users (all ages) across the UK

When our posts help to recruit participants for market research we earn a finder’s fee. These fees help with our running costs. By taking part or sharing our posts, you are helping to raise vital income for INPUT. Thank you!

 

Healthcare Opinions are organising a nationwide diabetes study looking to speak to people of all ages who are using an Accu-Chek Insight insulin pump to manage their diabetes. We have sessions available for the following pump users:

Adults (18+) who are using an Accu-Chek Insight insulin pump.
Adolescents (12-17) who are using an Accu-Chek Insight insulin pump.
Caregivers of children under the age of 12 who are using an Accu-Chek Insight insulin pump.

Participants will be asked to give their feedback on the design of a mobile app that will be used in conjunction with an insulin pump. During the session you will be asked to carry out a series of tasks, using the app loaded on a smartphone. The purpose of the study is to ensure the app is as simple to use as possible. The session is completely safe and non-invasive.

The Interview will last 1-hour and will be held in various central locations across the UK week commencing Monday 4th June, and as a thank you for taking part in the study you will receive £60.
All children, 17 years of age or younger, must be accompanied by an adult and they will receive an additional £15 as a thank you for attending too.

If this is something you are interested in and available for please head to the Healthcare Opinions website to answer a few short questions and register your interest. Or you can call their office on 0161 242 5215.

Please remember to mention INPUT when you are called to take part!

Posted in Market research | Comments Off on Market research: Accu-Chek Insight insulin pump users, all ages, across UK. £60 incentive

Update: Animas supplies of Dexcom G4

Following the news in January that Animas will close operations in the UK, Animas have advised that they are no longer supplying Dexcom G4 sensors.

They wrote to all the customers they knew about but some may not have heard.

Their letter explains how to get your Dexcom G4 supplies from now onward, whether you are self-funding or are funded by the NHS.

The letter, dated February 2018 can be viewed here

It said:

—–

Dexcom G4® PLATINUM CGM System – Update

We understand the trust and confidence you place in our products and company, and we recognize that you rely on our products to provide critical care and maintain your day-to-day health. Regrettably, we are writing to inform you that our agreement with Dexcom in relation to the supply of CGM products has come to an end. As a result, Animas will no longer be able to provide Dexcom G4® CGM from 1st April 2018. Effective immediately, Animas will begin transferring Dexcom product enquiries and requests to Dexcom.

What does this mean for you?

Private Purchases

If you are currently purchasing the Dexcom CGM yourself, we would recommend you contact Dexcom where you will be able to set up a direct account for continued supply. Dexcom can be contacted on:

Telephone: UK: 0800 031 5761
Email: UK: gb.sales@dexcom.com
Website: www.dexcom.com/en-GB

Funded by your Hospital/NHS Trust

If your Dexcom supplies are currently paid for by your Hospital/NHS Trust, we have contacted them to advise of the transition of supply direct from Dexcom. If your hospital orders CGM on your behalf, we would suggest you contact your Diabetes Team for clarification on how you proceed with future orders. If you currently order direct from Animas, we would recommend you contact Dexcom for further information. Dexcom can be contacted on the above details.

Troubleshooting
If you experience any issues with your Dexcom CGM products, now or in the future, whether obtained from Animas or Dexcom, please contact Dexcom on the above details.

—–

Dexcom told us: (we) can confirm that Animas doesn’t supply G4 sensors any longer since the 1st of April and Dexcom has taken over the distribution of G4 to Animas pump users. Dexcom will definitely continue to supply G4 sensors to all of them. However we know that not all Animas/Dexcom users are aware of this transition despite our communication efforts so any help will be appreciated.

As we said in the January news item:

Animas Vibe users will be able to continue to use their Animas Vibe and Animas consumables until the warranty expires, UNLESS your diabetes care team believe it would be detrimental to your health.

It does not mean all Animas Vibe users will be switched to Medtronic pumps against their wishes.

By February 2022 there will be no Animas Vibe pumps in warranty and no further consumables will be available.

Click here to see a copy of the letter Animas UK sent to their customers in January about their close down.

For answers to any questions about Animas pump supplies please reach out to the Animas Customer Support team on 0800 028 8039

To compare Animas Vibe form and functions with other pumps have a look at our comparison table here.

Posted in Product announcements, Uncategorized | Tagged , | Comments Off on Update: Animas supplies of Dexcom G4

Libre supplies restricted – again

The following message is from Abbott:

“Accelerating demand for the FreeStyle Libre system, paired with earlier than expected approvals and reimbursement in numerous countries, has led to shipping delays for web shop customers. We are working hard to address these issues and hope for the situation to be resolved by the summer.

We apologise for letting our customers down and we know these delays are unacceptable for the diabetes community. They’re unacceptable to us as well.

We are focused on providing access and we’re putting the following measures in place to resolve the current situation:
Until July, we are restricting access to our web shops to existing customers. Existing customers will be limited to ordering 2 sensors per shipment every 25 days.
We are offering all existing customers free shipping on orders until this delay is resolved.
We’re working on increasing our capacity and have also begun the process of building an additional manufacturing facility, which will further increase our output of sensors.

Those accessing the FreeStyle Libre system via NHS reimbursement should not be concerned about potential compromises to supply.”

What this means:

  • Global demand for Libre means sensors are in short supply
  • Prescriptions of Libre will not be affected
  • Existing web customers will be limited to a maximum order of 2 sensors every 25 days
  • The web shop will not accept any new customers until July 2018
  • Postage of web shop sensors will take longer than normal
  • You might get sensors quicker by buying from a pharmacy (check bit.ly/Libre222)

We are very disappointed with this restriction, and urge Abbott to sort out their manufacturing of sensors for the sake of people who rely on Libre.

While Abbott sort themselves out, you might consider trying Dexcom. G5 sensors are licensed for 7 days but many people make them last for 2-3 weeks or more, and the transmitters last for 3 months. You will need to register to see the offer.

Give Dexcom a try for just £160. This promotional offer includes a single sensor and a G5 transmitter at a 36% discount! Alternatively, they are offering 4 sensors and a G5 transmitter for £275, that’s a £130 discount! Please do give them a call to discuss the details. UK numbers 020 7139 1980 / 0330 088 7877 / 0800 031 5761

Posted in Product announcements | Tagged | Comments Off on Libre supplies restricted – again

Message from Insulet to OmniPod users in the UK

The following message is from Insulet:

We are pleased to announce an important update for Omnipod® Insulin Management System users in Europe. As the developer and manufacturer of the Omnipod® System, the team here at Insulet will be taking over all customer support and product services from      1 July 2018.

Introducing Insulet’s Customer Care team

To help keep you updated, we’re pleased to announce we have now setup our Customer Care team to be contacted by phone*. They will be available Monday-Friday from 8am-5pm (UK) and free to answer any questions users may have regarding our plans in Europe. The Customer Care team will not be signing up customers for products or services until      1 July 2018.

You can find contact details for the team on our newly updated webpage www.omnipodeurope.com where users can find plenty of helpful information about our plans.

Omnipod® System users should visit the page where they can register to receive email updates about our plans in Europe.

Until 1 July 2018, current distribution will remain the same and users are advised to continue to contact their current distributor to receive their Omnipod® System support as usual.

We believe that listening and responding to the diabetes community is important for us to support our customers’ needs now and in the future.

*Calls may be monitored and recorded for quality monitoring purposes. Calls to 0800 numbers are free from local landlines, but other networks may charge for these calls. Our Customer Care team will not be signing up customers for products or services until 1st July 2018. 

 

Posted in Product announcements | Tagged , | Comments Off on Message from Insulet to OmniPod users in the UK

Animas to close operations in UK

If you are an Animas Vibe user in the UK, you will have received a letter from Animas UK (or it is in the post) telling you that Animas UK will cease their operations in the UK as they did in the US in summer 2017. New pump sales will cease immediately. Consumables will continue to be available until the end of your pump’s warranty.

Animas is part of the global organisation Johnson & Johnson, who found global operations of Animas to be unprofitable. UK operations have been profitable but they are just a small part of the global brand.

We are disappointed by the loss of a major player in the pump arena here in the UK, and know that most Vibe users are very happy with their pumps.

The letter sets out the news and its implications, but you may still have some questions. Following conversations with Animas UK we hope to answer some of those questions below:

What does ‘preferred partner’ mean?

Nominating Medtronic as their ‘preferred partner’ allows Animas to ensure continuity of care after they have ceased operations. Animas insulin pump customers will get supplies and full customer care services from Animas for the duration of their warranty.

Local trusts may decide to terminate their contract with Animas and place it with Medtronic. At this point Medtronic will take over shipping your Animas supplies and will provide customer support for your Animas pump.  Or the trust and Medtronic may arrange to swap Animas Vibe users over to Medtronic pumps before the Animas pump warranty has expired.

Animas Vibe users will be able to continue to use their Animas Vibe and Animas consumables until the warranty expires, UNLESS your diabetes care team believe it would be detrimental to your health.

It does not mean all Animas Vibe users will be switched to Medtronic pumps against their wishes.

Dexcom G4 with Vibe

Those who are supplied by Animas with Dexcom G4 sensors (to use with Animas Vibe) will continue to receive their Dexcom supplies from Animas for the foreseeable future.

New Animas Vibe pumps on shelves

The 4 year warranty of Animas Vibe pumps commences on the date the pump is shipped from Animas. Therefore, if clinics have new Animas pumps on shelves waiting to be used these pumps will be supported until the warranty expires. For example if a clinic has had a new Animas Vibe in its store cupboard for one year and a patient starts to use it today, the warranty will run out after 3 years of use, and Animas will supply consumables and customer support for that 3 year period.

By February 2022 there will be no Animas Vibe pumps in warranty and no further consumables will be available.

One Touch brand to continue

For now, the One Touch brand of blood glucose meters and apps is unaffected, although it is under review by Johnson & Johnson (the brand owner).

Click here to see a copy of the letter Animas UK sent to their customers.

For answers to any questions please reach out to
the Animas Customer Support team on 0800 028 8039

To compare Animas Vibe form and functions with other pumps have a look at our comparison table here.

Posted in Uncategorized | Tagged | 1 Comment

Dexcom G5 price plan for existing customers

Do you self-fund a Dexcom G5? Their new subscription plan for existing customers could save you money!

For £160 per month you will get 4 x transmitters and 28 sensors.

Have a look at the various options by clicking on the link below

Dexcom G5 Price Plan Nov 2017 UK

Posted in Product announcements | Tagged , | Comments Off on Dexcom G5 price plan for existing customers

i-Port Advance injection port for MDI users

Medtronic are celebrating World Diabetes Day!

i-Port Advance™ is now available at a discounted price for a limited time only – offer ends 28 November 2017

How many times do you inject over 3 days?
Would you like to reduce that to one single skin puncture?

i-Port Advance is a small injection port that lets you take your insulin without having to puncture your skin for each injection. It’s easy to wear and easy to use, and both fast and long acting insulin can be injected into the same port. The port can be worn for up to three days during all normal activities, including sleeping, bathing and exercise.

 

 

Normally £72 online (ex VAT) for a box of 10 (1 month supply), from today until 28 November 2017 you can get a box of 10 for just £60 – the same price as at select Paydens pharmacies in the South East. Note this is currently not normally available on the NHS.

To find out more and take advantage of this offer click here

It won’t hurt to try…

What are the benefits?

iPort Advance™ has been proven to:

  • Reduce Pain
  • Reduce Anxiety
  • Improve quality of life

99% of patients report that i-Port Advance™ is beneficial
98% of patients think that i-Port Advance™ is comfortable to wear

What do patients say about i-Port Advance™?

“There were times before when diabetes restricted me. Parents would bring snacks and food to rehearsals and tennis matches, but I wouldn’t eat them because I didn’t want to take extra injections. Now, with i-Port Advance I can enjoy the food because I don’t mind taking the extra dose, and I feel just like any other teen in the room!”
Lindsey, age 16, has type 1 diabetes

To find out more and take advantage of this offer click here

Posted in Product announcements | Tagged , , | Comments Off on i-Port Advance injection port for MDI users

Access to Flash Glucose Monitoring (Flash GM)

Diabetes UK, INPUT and JDRF believe that Flash GM devices should be made available to any adult or child with type 1 diabetes, and to people with other forms of diabetes when intensive insulin therapy becomes necessary as outlined in our guideline.

Following campaigning across the diabetes community, from 1st November 2017 Flash GM will be made available on the NHS Drugs Tariff. This means in principle it is available to people with diabetes on NHS prescription.

It will now be up to local decision makers to draw-up policies about who can access the technology and in what ways.

Guidance on these local policies will come from specialists within the NHS and the final decisions on access will be made by local health decision makers.

Diabetes UK, INPUT and JDRF will work together to:

  • Ensure that the voices of people with diabetes are heard, and that their needs are forefront in decision-making.
  • Seek solutions to address barriers to access locally and nationally as they occur.
  • Inform people with diabetes about access and support people to know their rights.

We will continue to work together until those who would benefit and like to use Flash GM can easily and simply access it on the NHS.

Posted in News | Tagged | Comments Off on Access to Flash Glucose Monitoring (Flash GM)

New OneTouch Reveal mobile app

Press release by OneTouch on 12 September 2017

New OneTouch Reveal® Mobile App Empowers People with Diabetes to Manage their Blood Sugar and Easily Connects them with their Diabetes Care Support Network

Easy-to-use interconnected diabetes management system changes the way patients see their blood sugar readings and enables healthcare professionals, family, and friends to help them manage their condition

The new OneTouch Reveal® mobile app is now available in the UK and Ireland. It includes innovative, user-inspired features including blood sugar and activity timelines transformed into quick visual snapshots which allow people with diabetes to see their results, identify trends and get on with their daily life.

The new version of the OneTouch Reveal® mobile app has been designed to help patient engagement. It has an easy to use interface that changes the way patients see their blood sugar and manage their diabetes. In addition to the timeline and visual logbook, new features include a fingerprint login, an events newsfeed featuring relevant articles, a reminder function, averages for 14-, 30-, or 90- day time periods, and a break out of pre- and post-meal tagged results. The OneTouch Reveal® mobile app also uses ColorSure™ technology, which highlights patterns that show users a bigger picture.

 

Dr Iain Cranston, Consultant Physician at Portsmouth Hospitals NHS Trust said, “It is important that people with diabetes who test their blood sugar levels regularly are able to utilise the information from such tests to adjust therapies which may help with better overall control. Modern meters and apps (such as OneTouch Reveal®) which allow patients to easily assess patterns are thus an important part of this progressive process of improvement.”

 

The OneTouch Reveal® mobile app is the central component of the OneTouch® circle of support that connects patients to resources beyond devices. The OneTouch Reveal® mobile app seamlessly syncs with the OneTouch Verio Flex® blood glucose monitoring (BGM) system with built-in Bluetooth® Smart Technology. This connectivity enables users to see their blood glucose readings on the mobile app on their smart device and on their computer through the OneTouch Reveal® web app, and also makes it easier than ever for patients to share their data with their healthcare teams so that the teams can see their progress.

 

Chris Aldred, aka The Grumpy Pumper has been trying out the OneTouch Reveal® mobile app. He said “I’m not one for logging my data or messing about with cables for uploading it, I’ve got a life to live and it’s not going to be slowed down by my Diabetes. So at the times I do want to log my data, such as annual review time, being able to Bluetooth it across to the app is really useful.”

Martin Lambert, Head of Marketing UK&I, Johnson and Johnson Diabetes Care Companies (makers of OneTouch® products) said “We are delighted to launch the new OneTouch Reveal® mobile app and digital platform. We have designed the new interface with engaging social networking apps in mind, to appeal both to people with diabetes who are new to digital diabetes apps, as well as those who are more familiar with their use. Enhanced connectivity and the new user experience to help people with diabetes to quickly see and check their results, allowing them to make meaningful decisions and take an active role in their diabetes management.”

With more than 312,000 total downloads and 34 million plus blood glucose readings, the OneTouch Reveal® mobile app is one of the top downloaded diabetes apps globally.[1] In a clinical study, eight out of 10 people who had used the OneTouch Reveal® mobile app agreed that it helped them to better manage their blood glucose.[2]

About Johnson & Johnson Diabetes Care Companies (JJDCC)

With a shared vision of creating a world without limits for people with diabetes, the Johnson & Johnson Diabetes Care Companies are a collaboration of Johnson & Johnson companies dedicated to diabetes and includes LifeScan, Inc., a world leader in blood glucose monitoring; Animas Corporation, maker of innovative insulin delivery systems; Calibra Medical, Inc. developer of OneTouch Via™ on-demand insulin delivery; and the Johnson & Johnson Diabetes Institute, LLC, a global initiative to improve care and better outcomes worldwide through education and training programs. In the U.S., LifeScan, Inc. is the leading blood glucose monitoring company and OneTouch® brand products are recommended by more endocrinologists and primary care physicians than any other brand.[3] Globally, more than 20 million people depend on OneTouch® brand products to help them manage their diabetes. For more information, visit: www.myOneTouch.co.uk

 

Posted in Product announcements | Comments Off on New OneTouch Reveal mobile app

Patient representatives needed for Kent, Sussex & Surrey Diabetes Technology Collaborative

INPUT is delighted to be part of a type 1 diabetes adult service improvement project in Kent, Sussex & Surrey. Aimed at improving access to technology and reducing variation in access across the region, this 2 year project will be launched in October 2017.

The project is looking for 10 patient representatives (adult clinics) from across the region, who use insulin pumps or CGM and have experience of receiving care with their local team. If you transferred to a London clinic in order to access pump therapy you would also be welcome as long as you still live in the KSS area.

It is hoped that patient representatives will be joined up with their local Trust team during the 4 quality improvement workshop events where the Trust teams would be reviewing why in their service patients are experiencing difficulty in accessing medical technology and how access can be improved.

Patient representatives will need to commit to attend all 4 workshop days, to be held in the KSS region, and the workshops will run from around 9am to 4:30pm.

The workshop event days are

Workshop 1, Wednesday, 18 October 2017

Workshop 2, 28th February 2018

Workshop 3, 13th June 2018

Workshop 4, 19th September 2018

If you would like to be considered, please email
kssahsn.diabetes@nhs.net

Posted in Service improvement | Comments Off on Patient representatives needed for Kent, Sussex & Surrey Diabetes Technology Collaborative